[vc_row][vc_column][ultimate_heading main_heading="Latest DPCO Price List by the Government"][/ultimate_heading][/vc_column][/vc_row][vc_row][vc_column width="1/2"][vc_column_text][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-01.pdf" title="dpco price list nov 2018 01"][/vc_column_text][/vc_column][vc_column width="1/2"][vc_column_text][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-02.pdf" title="dpco price list nov 2018 02"][vc_row][vc_column width="1/2"][vc_column_text][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-03.pdf" title="dpco price list nov 2018 03"][/vc_column_text][/vc_column][vc_column width="1/2"][vc_column_text][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-04.pdf" title="dpco price list nov 2018 04"][pdf-embedder url="https://vibcare.co.in/wp-content/uploads/2019/03/dpco-price-list-nov-2018-05.pdf" title="dpco price list nov 2018 05"]2nd November 2018

ORDER

S.O. 5633(E) In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table hereinbelow as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column

(2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Note: 

• All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if
• All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO,
• The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said
• The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and
• As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
• Where an existing manufacturer of a scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing

the manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

• The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
• The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,
• Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)

2nd November 2018

ORDER

S.O. 5634(E) In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th  March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers,  and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1462(E), dated 2nd April 2018, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Note: 

• All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if
• All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO,
• The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said
• The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and
• As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
• Where an existing manufacturer of a scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing

the manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

• The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
• The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,
• Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)

2nd November 2018

ORDER

1. O. 5635(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table hereinbelow passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column

• of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table hereinbelow as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company , as specified in the corresponding entries in columns (3), (4) and (8) thereof;

Table

Note:

• The manufacturer of above-mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table
• The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said
• The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and
• As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
• The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
• In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act,

2nd November 2018

ORDER

 S.O. 5636(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table hereinbelow passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table hereinbelow as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Note:

• All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if
• All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO,
• The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said
• The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and

• As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
• Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO,
• The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
• The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,
• Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)

2nd November 2018

ORDER

1. O. 5638(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table hereinbelow as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Note:

• The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table

• The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said
• The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and
• As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
• The above mentioned retail price is applicable only to the individual manufacturer / marketeer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing
• In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act,
• Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)

DPCO Price List - March 2019

Latest Notification on DPCO Price List

ORDER

S.O. 1462(E) In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table hereinbelow as ceiling prices exclusive of goods and services tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Price Revision as per Annual Wholesale Price Index (WPI) @ 3.43812% increase

SlNo

Medicines

Dosage form andStrength

Unit

Ceilingprice (wef 01.4.2018

with WPI

@ 3.43812%)Existing S.O. No. &Date(1)(2)(3)(4)(5)6(a)6(b)1Acetyl Salicylic AcidTablet 300mg1 Tablet0.212432060(E)30.06.20172Calcium carbonateTablet 250 mg1 Tablet1.832060(E)30.06.20173Calcium carbonateTablet 500 mg1 Tablet1.822060(E)30.06.20174Condoms
1 Condom8.562061(E)30.06.20175DapsoneTablet 50 mg1 Tablet0.221502061(E)30.06.20176DaunorubicinInjection 20 mgEach Pack400.742061(E)30.06.20177Ethyl Alcohol 70%Solution
1 ML0.542060(E)30.06.20178EtoposideCapsules 100 mg1 Capsule56.832060(E)30.06.20179Framycetin SulphateCream 0.50%1 GM0.822060(E)30.06.201710Gentian Violet Paint1%1 ML0.061332060(E)30.06.201711IsoniazidSyrup 100 mg/5ml1 ML0.242602061(E)30.06.201712Medroxy Progesterone AcetateTablet 5mg1 Tablet2.82060(E)30.06.201713Nitrous Oxide Inhalation
Cubic Meter224.052060(E)30.06.201714Oral Poliomyelitisvaccine (LA)Solution1 ML113.192061(E)30.06.201715Oxygen Inhalation
Cubic Meter17.192060(E)30.06.201716PraziquantelTablet 600 mg1 Tablet27.062061(E)30.06.201717RifampicinTablet 450mg1 Tablet4.162060(E)30.06.201718Sodium NitriteInjection 30mg/ml1 ML20.252060(E)30.06.2017

Notes:-

• The ceiling prices are applicable with effect from 4.2018 (ceiling prices are inclusive of Wholesale Price Index (WPI) @3.43812% for the year 2017 over 2016).
• All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services taxes as applicable, if
• All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services taxes as applicable, if any), may revise the existing R.P. of their formulations, on the basis of WPI @ 3.43812% for year 2017 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.
• The manufacturers may add goods and services taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said
• The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned

manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

• As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
• Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO,
• The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
• The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,
• Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

2nd April 2018

ORDER

S.O. 1463(E) In exercise of powers, conferred by subparagraph (3) and (4) of paragraph 11 and paragraph 14 of the Drugs (Prices  Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013,  S.O. 1192(E)  dated 22nd  March 2016  issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O 1993(E) dated 3rd June 2016 read with Corrigendum order S.O 2062 dated 9th June 2016, S.O 2210(E) dated 24th June 2016,  S.O  2578(E)  dated  1st August 2016, S.O. 3161(E) dated 6th October 2016, S.O. 1051(E) dated 1st April 2017 and

S.O. 2062(E) dated 30th June 2017 in so far as they relate to formulation packs of Non-Glass with special features (mentioned as Non-PVC in S.O. 1993(E)  dated 3rd June 2016) mentioned in the Table A hereinbelow, manufactured by the manufacturers  specified  in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2017 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of goods and services tax applicable, if any in respect of the scheduled formulations  specified  in  the  corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table A: Price Revision as per Annual Wholesale Price Index (WPI) @ 3.43812% increase.

with WPI @ 3.43812%)(1)(2)(3)(4)(5)1GlucoseInjection 5%1000ml Non-Glass withspecial features71.702GlucoseInjection 5%500ml Non-Glass withspecial features62.033Glucose (A) +Sodium Chloride (B)Injection 5% (A) +0.9% (B)1000ml Non-Glass withspecial features75.354Glucose (A) +Sodium Chloride (B)Injection 5% (A) +0.9% (B)500ml Non-Glass with special features64.475Sodium ChlorideInjection 0.9%100ml Non-Glass withspecial features31.716Sodium ChlorideInjection 0.9%250ml Non-Glass withspecial features46.827Sodium ChlorideInjection 0.9%500ml Non-Glass withspecial features66.308Glucose (A) +Sodium Chloride (B)Injection 5% (A) +0.9% (B)1000ml Non-Glass with special features74.26

TABLE ‘B’

• The ceiling prices are applicable with effect from 4.2018 (ceiling prices are inclusive of Wholesale Price Index (WPI) @3.43812% for the year 2017 over 2016).
• The manufacturers of scheduled formulations, selling abovesaid products/brand name of

scheduled formulations at price higher than the  ceiling  price (plus  goods  and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the  ceiling  price specified in column (5) in the above table plus goods and services tax as applicable, if any.

• The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services  tax  as applicable, if any),  may  revise the existing R.P.  of their  formulations , on the basis of WPI @ 3.43812% for year 2017 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.
• The manufacturers may add goods and  services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said
• Any other manufacturer claiming separate ceiling price for Non-Glass  with  special feature shall apply to NPPA for separate ceiling price approval with details and  demonstrate, that such pack has all of the features as (i) self collapsibility and self- sealability (ii) not having air-vent; and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels along with documentation and
• For other special features claimed or any other pack size manufactured,  the manufacturer shall approach the NPPA for specific price approval for its formulation
• The ceiling price for a pack of the scheduled formulation shall be arrived at by the

concerned manufacturer in accordance with the ceiling price specified in column (5)  of the above table as per provisions contained in paragraph 11 of  the  Drugs  (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to  NPPA  through  IPDMS  and submit a copy to State Drug Controller and dealers.

• As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the

• Where an existing manufacturer of scheduled  formulation  with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO,
• The manufacturers of above said scheduled  formulations  shall furnish quarterly  return  to the NPPA,  in  respect of production/import and sale of scheduled formulations in Form -III  of Schedule-II  of the DPCO, 2013 through  Any manufacturer  intending  to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of  discontinuation  of  production and/or import of  scheduled formulation in  Form-IV of  Schedule-II of the DPCO, 2013 at least six months prior  to the intended date  of discontinuation.
• The manufacturers not complying with the ceiling price and notes  specified  hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,
• Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail  price,  if  any, issued prior to the above said date of notification, stand(s)

2nd April 2018

ORDER

SO 1464(E) In partial modification of the notification issued by National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemical and Fertilizers vide S.O. 639(E) dated 12.02.2018, regarding the  fixation of  ceiling  price  of  the  coronary  stents,  after considering the  Wholesale  Price  Index  (WPI)  @  3.43812 percent for the year 2017 over 2016,  It has been decided to revise the ceiling prices exclusive of goods and services tax applicable with effect from 01.04.2018 as mentioned in the table in para 13 of the original notification as follows:

TABLE

All the terms and conditions/notes as mentioned in the original order dated 12.02.2018 thereto shall remain same.2nd April 2018

ORDER

S.O. 1461(E) In exercise of the powers, conferred by paragraph 4, 6, 10, 11,  14,  16,  17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May 2013 issued by the Government of India in the Ministry of Chemicals and   Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry  of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O.  Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of goods and services tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table: Price Revision as per Annual Wholesale Price Index (WPI) @ 3.43812% increase.

with WPI

@ 3.43812%)Existing S.O. No. &Date(1)(2)(3)(4)(5)6(a)6(b)15-aminosalicylic AcidSuppository 500mg Retention Enema1 Suppository15.872058(E)30.06.201725-aminosalicylic AcidTablet 400 mg1 Tablet7.012058(E)30.06.201735-FluorouracilInjection 250mg/5 ml1 ml2.202059(E)30.06.201746-MercaptopurineTablet 50mg1 Tablet6.062398(E)28.07.20175AbacavirTablet 300 mg1 Tablet44.262058(E)30.06.20176Abacavir (A) + Lamivudine (B)Tablet 60 mg(A)+ 30 mg(B)1 Tablet18.852400(E)28.07.20177Abacavir (A) + Lamivudine (B)Tablet 600mg(A)+ 300

mg(B)1 Tablet85.532400(E)28.07.20178AcetazolamideCapsule 250 mg1 Capsule4.252059(E)30.06.20179AcetazolamideTablet 250 mg1 Tablet3.432059(E)30.06.201710Acetylsalicylic acidEffervescent/ Dispersible/ Enteric  coatedTablet 100 mg1 Tablet0.168093722(E)23.11.2017

(B)/5 ml1 ml2.032058(E)30.06.201748Amoxicillin (A) + Clavulanicacid (B)Oral Liquid 200mg(A) + 28.5

mg(B)/5ml1 ml1.702058(E)30.06.201749Amoxicillin (A) + Clavulanic acid (B)Powder for Injection 500mg(A)  + 100

mg(B)Each Pack84.502058(E)30.06.201750Amoxicillin (A) +Clavulanic acid (B)Tablet 500mg(A)+125mg(B)1 Tablet16.862401(E)28.07.201751Amoxicillin (A) +Clavulanic acid (B)Powder for Injection 1g (A)+200mg(B)Each Pack117.872401(E)28.07.201752Amphotericin B - Lipid/LiposomalPowder forInjection 50 mgEach Pack3,519.53269(E)16.01.201853Amphotericin B –ConventionalPowder forInjection 50 mgEach Pack290.712059(E)30.06.201754AmpicillinPowder forInjection 1 gmEach Pack20.042058(E)30.06.201755AmpicillinPowder for Injection 500 mgEach Pack12.342058(E)30.06.201756Anti-D immunoglobulinInjection 300mcgEach Pack2,003.413723(E)23.11.201757Anti-D ImmunoglobulinInjection 150mcgEach Vial1,561.593913(E)18.12.201758Anti-rabies immunoglobulinInjection 150 IU/ml1 ml2,603.952059(E)30.06.201759Anti-rabies immunoglobulinInjection 300IU/ml1 ml91.802059(E)30.06.201760Anti-tetanus immunoglobulin
Each Pack773.783090(E)20.09.201761Arsenic TrioxideInjection 1mg/ml1 ml50.972397(E)28.07.201762Artemether (A) + Lumefantrine (B)Oral Liquid 80mg(A) +480

mg(B) /5ml1 ml3.792058(E)30.06.201763Artemether  (A) +Lumefantrine  (B)Tablet 20 mg(A)+ 120 mg(B)1 Tablet11.752058(E)30.06.201764Artemether  (A) +Lumefantrine  (B)Tablet 40 mg(A)+ 240 mg(B)1 Tablet15.142058(E)30.06.201765Artemether  (A) +Lumefantrine  (B)Tablet 80 mg(A)+ 480 mg(B)1 Tablet21.742058(E)30.06.201766ArtesunatePowder forInjection 120 mgEach Pack390.572059(E)30.06.201767ArtesunatePowder forInjection 60 mgEach Pack205.152059(E)30.06.201768Artesunate (A) +Sulphadoxine - Pyrimethamine (B)Tablet  100 mg(A)+ 1 Tablet (750 mg+  37.5 mg) (B)Combi pack27.693091(E)20.09.201769Artesunate (A) + Sulphadoxine -Pyrimethamine (B)Tablet 150 mg(A)+ 2 Tablet (500 mg+ 25 mg) (B)Combi pack37.593091(E)20.09.2017

(500 mg+ 25 mg) (B)Combi Pack19.922058(E)30.06.201773Ascorbic Acid (Vitamin C)Tablet 100mg1 Tablet0.182083090(E)20.09.201774Ascorbic Acid (Vitamin C)Tablet 500 mg1 Tablet0.852058(E)30.06.201775Atazanavir (A) + Ritonavir (B)Tablet 300 mg(A)+ 100 mg(B)1 Tablet92.662400(E)28.07.201776AtenololTablet 100 mg1 Tablet3.272058(E)30.06.201777AtenololTablet 50 mg1 Tablet1.682058(E)30.06.201778AtorvastatinTablet 10 mg1 Tablet5.152058(E)30.06.201779AtorvastatinTablet 20 mg1 Tablet12.472058(E)30.06.201780AtorvastatinTablet 40 mg1 Tablet18.112058(E)30.06.201781AtracuriumInjection 10 mg/mlEach Pack49.202058(E)30.06.201782AtropineOintment 1%1 gm3.552400(E)28.07.201783AtropineInjection 0.6mg/ml1 ml3.932400(E)28.07.201784AtropineDrops 1%1 ml3.222400(E)28.07.201785AzathioprineTablet 50 mg1 Tablet9.522059(E)30.06.201786AzithromycinCapsule 250 mg1 Capsule9.862058(E)30.06.201787AzithromycinCapsule 500 mg1 Capsule15.562058(E)30.06.201788AzithromycinOral Liquid 200 mg/5ml1 ml2.892058(E)30.06.201789AzithromycinTablet 250mg1 Tablet9.912401(E)28.07.201790AzithromycinTablet 500mg1 Tablet19.992401(E)28.07.201791AzithromycinPowder for Injection 500mgEach Pack180.452401(E)28.07.201792BaclofenTablet 10 mg1 Tablet10.092059(E)30.06.201793BaclofenTablet 20 mg1 Tablet13.892059(E)30.06.201794BaclofenTablet 5 mg1 Tablet5.202059(E)30.06.201795BCG vaccine
Each Dose4.473723(E)23.11.201796Benzathine benzylpenicillinPowder for Injection 12 lacunitsEach Pack11.402058(E)30.06.201797Benzathine benzylpenicillinPowder forInjection 6 lac unitsEach Pack7.552058(E)30.06.201798Benzoyl PeroxideCream 2.5%1 gm2.202058(E)30.06.201799Benzoyl PeroxideGel 2.5%1 gm3.522058(E)30.06.2017100Benzyl penicillinPowder for Injection 10 Lac UnitsEach Pack4.882601(E)11.08.2017101BetamethasoneCream 0.05%1 gm0.552058(E)30.06.2017102BetamethasoneCream 0.1%1 GM0.792397(E)28.07.2017

mcg/dose1 Dose1.232058(E)30.06.2017113BudesonideInhalation (MDI/DPI) 200mcg/dose1 Dose1.522058(E)30.06.2017114BudesonideNasal Spray 100 mcg/dose1 Dose0.852058(E)30.06.2017115BudesonideNasal Spray 50 mcg/dose1 Dose0.952058(E)30.06.2017116BudesonideRespiratory Solution for use in Nebulizer 0.5mg/ml1 ml10.052058(E)30.06.2017117BudesonideRespiratory Solution for usein Nebulizer 1 mg/ml1 ml12.122058(E)30.06.2017118Budesonide (A)+ Formoterol (B)Inhalation (MDI/DPI) 100mcg (A) + 6 mcg

(B)1 Dose1.762058(E)30.06.2017119Budesonide (A)+ Formoterol(B)Inhalation(MDI/DPI) 200

mcg (A) + 6 mcg (B)1 Dose2.212058(E)30.06.2017120Budesonide (A)+ Formoterol (B)Inhalation (MDI/DPI) 400mcg (A) + 6 mcg (B)1 Dose2.772058(E)30.06.2017121BupivacaineInjection 0.25%1 ml2.302058(E)30.06.2017122BupivacaineInjection 0.5%with 7.5% glucose1 ml5.832058(E)30.06.2017123BupivacaineInjection 0.50%1 ml3.682058(E)30.06.2017124CaffeineInjection 20 mg/ml1 ml235.592058(E)30.06.2017125CaffeineOral Liquid 20mg/ml1 ml200.092058(E)30.06.2017

dilution)1 ml0.146823090(E)20.09.2017170ChloroquineOral Liquid 50mg/5ml1 ml0.282059(E)30.06.2017171ChloroquineTablet 150mg1 Tablet0.743729(E)23.11.2017172ChlorpheniramineTablet 4 mg1 Tablet0.086122058(E)30.06.2017173CholecalciferolCapsule 1000 IU1 Capsule4.482058(E)30.06.2017174CholecalciferolCapsule 60000 IU1 Capsule27.722058(E)30.06.2017175CholecalciferolOral Liquid 400 IU/ml1 ml2.212058(E)30.06.2017176CholecalciferolTablet 1000 IU1 Tablet3.522058(E)30.06.2017177CholecalciferolTablet 60000 IU1 Tablet22.762058(E)30.06.2017178CiprofloxacinOintment 0.3%1 gm1.062058(E)30.06.2017179CiprofloxacinDrops 0.30%1 ml1.432058(E)30.06.2017180CiprofloxacinInjection 200 mg/100ml1 ml0.158412058(E)30.06.2017181CiprofloxacinOral Liquid 250mg/5ml1 ml0.592058(E)30.06.2017182CiprofloxacinTablet 250mg1 Tablet1.952401(E)28.07.2017183CiprofloxacinTablet 500mg1 Tablet3.422401(E)28.07.2017184CisplatinInjection 1mg/ml1 ml6.462058(E)30.06.2017185ClarithromycinOral Liquid 125mg/5ml1 ml4.052058(E)30.06.2017186ClarithromycinTablet 250 mg1 Tablet26.282058(E)30.06.2017187ClarithromycinTablet 500 mg1 Tablet46.322058(E)30.06.2017188ClindamycinCapsule 150 mg1 Capsule13.582059(E)30.06.2017189ClindamycinCapsule 300 mg1 Capsule22.172059(E)30.06.2017190ClindamycinTablet 300 mg1 Tablet14.312059(E)30.06.2017191ClobazamTablet 10 mg1 Tablet8.482058(E)30.06.2017192ClobazamTablet 5 mg1 Tablet4.822058(E)30.06.2017193ClofazimineCapsule 100 mg1 Capsule2.322059(E)30.06.2017194ClofazimineCapsule 50 mg1 Capsule1.362059(E)30.06.2017195ClomipheneCapsule 100 mg1 Capsule52.242058(E)30.06.2017196ClomipheneCapsule 50 mg1 Capsule28.742058(E)30.06.2017197ClomipheneTablet 100mg1 Tablet11.46650(E)13.02.2018

(A)+Trimethoprim (B)]Tablet 800mg(A)+160

mg(B)1 Tablet0.992058(E)30.06.2017224CyclophosphamideTablet 50 mg1 Tablet3.812059(E)30.06.2017225CyclophosphamidePowder for Injection 500 mgEach Pack74.912059(E)30.06.2017226CycloserineCapsule 250 mg1 Capsule50.962058(E)30.06.2017227CycloserineTablet 250 mg1 Tablet43.812058(E)30.06.2017228CyclosporineCapsule 100 mg1 Capsule96.212059(E)30.06.2017229CyclosporineCapsule 25 mg1 Capsule25.822059(E)30.06.2017230CyclosporineCapsule 50 mg1 Capsule49.412059(E)30.06.2017231CyclosporineInjection 50 mg/ml1 ml253.162059(E)30.06.2017232CyclosporineOral Liquid 100mg/ml1 ml88.722059(E)30.06.2017233Cytosine arabinosideInjection 100 mg/mlEach Pack186.472059(E)30.06.2017234Cytosine arabinosidePowder forEach Pack1,005.742059(E)30.06.2017

mg(B)1 Tablet3.242059(E)30.06.2017310EthionamideTablet 250 mg1 Tablet14.822058(E)30.06.2017311EtoposideCapsule 50 mg1 Capsule51.032058(E)30.06.2017312EtoposideInjection 20mg/ml1 ml33.652058(E)30.06.2017313FentanylInjection50mcg/ml1 ml21.312058(E)30.06.2017314Ferrous salt (A) + Folic acid(B)Oral liqiud 20mgelemental iron

(A) + 100mcg (B)/ml1 ml0.124893091(E)20.09.2017315Ferrous salt (A) + Folic acid (B)Tablet 100 mg elemental iron(A) + 500 mcg (B)1 Tablet0.101593091(E)20.09.2017316Ferrous salt (A) + Folic acid(B)Tablet45mgelemental

iron (A) + 400 mcg (B)1 Tablet0.131943091(E)20.09.2017317FilgrastimInjection 300mcgEach pack1,288.032058(E)30.06.2017318FluconazoleCapsule 100 mg1 Capsule23.712058(E)30.06.2017319FluconazoleCapsule 150 mg1 Capsule17.412058(E)30.06.2017320FluconazoleCapsule 200 mg1 Capsule34.272058(E)30.06.2017321FluconazoleOral Liquid 50mg/5ml1 ml2.463088(E)11.08.2017322FluconazoleTablet 100 mg1 Tablet7.492058(E)30.06.2017323FluconazoleTablet 150 mg1 Tablet11.122058(E)30.06.2017324FluconazoleTablet 200 mg1 Tablet17.632058(E)30.06.2017325FluconazoleTablet 400 mg1 Tablet29.322058(E)30.06.2017326FluconazoleInjection 200 mg/100 mlEach Pack99.892058(E)30.06.2017327FlunarizineTablet 10 mg1 Tablet4.442058(E)30.06.2017328FlunarizineTablet 5 mg1 Tablet2.592058(E)30.06.2017329FluoxetineCapsule 10 mg1 Capsule2.792058(E)30.06.2017330FluoxetineCapsule 20 mg1 Capsule3.422058(E)30.06.2017331FluoxetineCapsule 40 mg1 Capsule5.202058(E)30.06.2017332FluoxetineCapsule 60 mg1 Capsule9.192058(E)30.06.2017333FluoxetineTablet 10 mg1 Tablet2.342058(E)30.06.2017334FluoxetineTablet 20 mg1 Tablet3.722058(E)30.06.2017335FluoxetineTablet 40 mg1 Tablet5.012058(E)30.06.2017336FluoxetineTablet 60 mg1 Tablet6.942058(E)30.06.2017337FluphenazineDepot Injection 25 mg/ml1 ml46.962058(E)30.06.2017338Folic AcidCapsule 5 mg1 Capsule5.292058(E)30.06.2017

mg(C)1 Tablet14.652400(E)28.07.2017457Lamivudine (A) + Zidovudine(B)Tablet 150 mg(A)+ 300 mg(B)1 Tablet18.832400(E)28.07.2017458Lamivudine (A)+ Nevirapine(B) + Stavudine (C)DispersibleTablet 30 mg(A)

+ 50 mg(B) + 6

mg(C)1 Tablet4.642400(E)28.07.2017459L-AsparaginasePowder for Injection 10000KUEach Pack1,506.742058(E)30.06.2017460L-AsparaginasePowder for Injection 5000KUEach Pack972.592058(E)30.06.2017461LeflunomideTablet 10 mg1 Tablet9.402058(E)30.06.2017462LeflunomideTablet 20 mg1 Tablet18.342058(E)30.06.2017463LetrozoleTablet 2.5 mg1 Tablet38.272059(E)30.06.2017464LevetiracetamInjection 100 mg/ml1 ml20.482058(E)30.06.2017465LevetiracetamER Tablet 750mg1 Tablet16.322058(E)30.06.2017466LevetiracetamTablet 250 mg1 Tablet5.492058(E)30.06.2017467LevetiracetamTablet 500 mg1 Tablet11.102058(E)30.06.2017468LevetiracetamTablet 750 mg1 Tablet17.062058(E)30.06.2017469LevetiracetamOral Liquid 100 mg/ml1 ml3.422058(E)30.06.2017470Levodopa (A) + Carbidopa (B)CR Tablet 100mg(A) + 25

mg(B)1 Tablet3.132058(E)30.06.2017471Levodopa (A) + Carbidopa (B)Tablet 100 mg(A)+ 10 mg(B)1 Tablet1.462058(E)30.06.2017

mg(B)1 Tablet3.862058(E)30.06.2017475LevofloxacinTablet 250 mg1 Tablet4.142058(E)30.06.2017476LevofloxacinTablet 750 mg1 Tablet10.262058(E)30.06.2017477LevofloxacinTablet 500mg1 Tablet7.572401(E)28.07.2017478LevonorgestrelTablet 0.75 mg1 Tablet21.612058(E)30.06.2017479LevothyroxineTablet 100 mcg1 Tablet1.122058(E)30.06.2017480LevothyroxineTablet 112mcg1 Tablet1.342397(E)28.07.2017481LevothyroxineTablet 12.5 mcg1 Tablet1.272058(E)30.06.2017482LevothyroxineTablet 125 mcg1 Tablet1.442058(E)30.06.2017483LevothyroxineTablet 150 mcg1 Tablet1.452058(E)30.06.2017484LevothyroxineTablet 25 mcg1 Tablet1.232058(E)30.06.2017485LevothyroxineTablet 50 mcg1 Tablet0.922058(E)30.06.2017486LevothyroxineTablet 62.5mcg1 Tablet1.312397(E)28.07.2017487LevothyroxineTablet 75 mcg1 Tablet1.222058(E)30.06.2017488LevothyroxineTablet 88 mcg1 Tablet1.442058(E)30.06.2017489LignocaineInjection 2%1 ml0.922058(E)30.06.2017490LignocaineInjection 2%(Preservative free for IV use)1 ml0.912058(E)30.06.2017491LignocaineInjection 1%Each Pack7.452058(E)30.06.2017492LignocaineTopical Forms 2-5%1 gm or 1 ml1.01650(E)13.02.2018493LignocaineInjection 5%with 7.5% Glucose1 ml3.452058(E)30.06.2017494Lignocaine (A) + Adrenaline (B)Injection 1% (A)+ 1:200000 (5

mcg/ml) (B)1 ml0.423725(E)23.11.2017495Lignocaine (A) + Adrenaline (B)Injection 2% (A)+ 1:200000

(5mcg/ml) (B)1 ml0.862058(E)30.06.2017496LinezolidTablet 600 mg1 Tablet31.012058(E)30.06.2017497LithiumTablet 300 mg1 Tablet1.372058(E)30.06.2017498LoperamideCapsule 2 mg1 Capsule3.362058(E)30.06.2017499LoperamideTablet 2 mg1 Tablet1.852058(E)30.06.2017500Lopinavir (A) + Ritonavir (B)Tablet 100 mg(A)+ 25 mg(B)1 Tablet22.072400(E)28.07.2017501Lopinavir (A) + Ritonavir (B)Tablet 200 mg(A)+ 50 mg(B)1 Tablet42.772400(E)28.07.2017502Lorazepaminjection 2 mg/ml1 ml7.302058(E)30.06.2017503LorazepamTablet 1 mg1 Tablet1.942058(E)30.06.2017504LorazepamTablet 2 mg1 Tablet2.362058(E)30.06.2017505Magnesium SulphateInjection 500 mg/ml1 ml4.482058(E)30.06.2017

1000 mg1 Tablet3.422058(E)30.06.2017524MetforminControlledRelease Tablet 500 mg1 Tablet1.792058(E)30.06.2017525Metformincontrolled Released Tablet750 mg1 Tablet2.252058(E)30.06.2017526MetforminImmediateRelease Tablet 1000 mg1 Tablet3.382058(E)30.06.2017527MetforminImmediateRelease Tablet

750 mg1 Tablet2.852058(E)30.06.2017528MethotrexateInjection 25mg/ml1 ml45.142059(E)30.06.2017529MethotrexateInjection 50mg/ml1 ml37.602059(E)30.06.2017530MethotrexateTablet 10 mg1 Tablet11.402059(E)30.06.2017531MethotrexateTablet 2.5 mg1 Tablet4.492059(E)30.06.2017532MethotrexateTablet 7.5 mg1 Tablet10.882059(E)30.06.2017533MethotrexateTablet 5 mg1 Tablet7.862059(E)30.06.2017534MethyldopaTablet 250 mg1 Tablet2.292058(E)30.06.2017535MethyldopaTablet 500 mg1 Tablet4.392058(E)30.06.2017536MethylergometrineInjection 0.21 ml13.402058(E)30.06.2017

Pack)1 ml1.332058(E)30.06.2017542MetoclopramideInjection 5mg/ml (2 ml Pack)1 ml2.202058(E)30.06.2017543MetoclopramideOral Liquid 5mg/5ml1 ml0.412058(E)30.06.2017544MetoclopramideTablet 10 mg1 Tablet1.092058(E)30.06.2017545MetoprololCapsule 25 mg1 Capsule3.972058(E)30.06.2017546MetoprololCapsule 50 mg1 Capsule6.052058(E)30.06.2017547MetoprololSR Tablet 25 mg1 Tablet3.792058(E)30.06.2017548MetoprololSR Tablet 50 mg1 Tablet5.422058(E)30.06.2017549MetoprololTablet 25 mg1 Tablet2.922058(E)30.06.2017550MetoprololTablet 50 mg1 Tablet4.422058(E)30.06.2017551MetronidazoleInjection 500mg/100ml1 ml0.12557352(E)23.01.2018552MetronidazoleOral Liquid 200 mg/5ml1 ml0.282058(E)30.06.2017553MetronidazoleTablet 200 mg1 Tablet0.402058(E)30.06.2017554MetronidazoleTablet 400 mg1 Tablet0.762058(E)30.06.2017555MidazolamInjection 1 mg/ml1 ml5.542058(E)30.06.2017556MidazolamInjection 5mg/ml1 ml13.622058(E)30.06.2017557MidazolamTablet 7.5mg1 Tablet21.072601(E)11.08.2017558MifepristoneTablet 200 mg1 Tablet301.962058(E)30.06.2017559MisoprostolTablet 100 mcg1 Tablet8.172058(E)30.06.2017560MisoprostolTablet 200 mcg1 Tablet15.672058(E)30.06.2017561MorphineInjection 10mg/ml1 ml22.292058(E)30.06.2017562MorphineInjection 15 mg/ml1 ml27.812058(E)30.06.2017563MorphineSR Tablet 30 mg1 Tablet5.113724(E)23.11.2017564MorphineTablet 10 mg1 Tablet5.002058(E)30.06.2017565MoxifloxacinTablet 400 mg1 Tablet23.782058(E)30.06.2017566Mycophenolate mofetilTablet 250 mg1 Tablet38.972059(E)30.06.2017567Mycophenolate mofetilTablet 500 mg1 Tablet77.092059(E)30.06.2017568N-acetylcysteineInjection 200mg/ml1 ml21.032058(E)30.06.2017569N-acetylcysteineSachet 200mg1 gm8.44269(E)16.01.2018570Naloxoneinjection 0.4 mg/ml1 ml81.432058(E)30.06.2017571NatamycinDrops 5%1 ml21.412058(E)30.06.2017572Neostigmineinjection 0.51 ml4.092058(E)30.06.2017

+ 125 mg(B)Each Pack82.972058(E)30.06.2017655Piperacillin (A) + Tazobactam (B)Powder for Injection 2 g (A)+ 250 mg(B)Each Pack196.282058(E)30.06.2017656Piperacillin (A) + Tazobactam (B)Powder for Injection 4 g (A)+ 500 mg(B)Each Pack412.312058(E)30.06.2017657Potassium chlorideInjection 150mg/ml1 ml2.282058(E)30.06.2017658Potassium chlorideOral Liquid 500mg/5ml1 ml0.272058(E)30.06.2017659Potassium permanganateCrystals fortopical solution1 gm0.413725(E)23.11.2017660Povidone iodineSolution 4%1 ml1.632058(E)30.06.2017661Povidone iodineSolution 7.5%1 ml0.732058(E)30.06.2017662Povidone IodineSolution 10%1 ml0.79650(E)13.02.2018663Povidone IodineSolution 5%1 ml0.362401(E)28.07.2017664Pralidoxime chloride (2-PAM)Injection 25 mg/ml1 ml3.502058(E)30.06.2017665PrednisoloneDrops 1%1 ml3.152058(E)30.06.2017666PrednisoloneInjection 20mg/2ml1 ml3.362058(E)30.06.2017667PrednisoloneOral Liquid 15mg/ 5ml1 ml0.712058(E)30.06.2017668PrednisoloneOral Liquid 5mg/ 5ml1 ml0.402058(E)30.06.2017669PrednisoloneTablet 10 mg1 Tablet0.912058(E)30.06.2017670PrednisoloneTablet 20 mg1 Tablet1.832058(E)30.06.2017671PrednisoloneTablet 40 mg1 Tablet2.642058(E)30.06.2017672PrednisoloneTablet 5 mg1 Tablet0.532058(E)30.06.2017

mg/ml1 ml0.662058(E)30.06.2017731SalbutamolTablet 2 mg1 Tablet0.152058(E)30.06.2017732SalbutamolTablet 4 mg1 Tablet0.171972058(E)30.06.2017733Salicylic acidOintment 6%1 gm1.692058(E)30.06.2017734SevofluraneInhalation1 ml24.953723(E)23.11.2017735Silver SulphadiazineCream 1%1 gm0.283089(E)20.09.2017736Snake venom antiserum- Lyophilized polyvalentPowder for Injection10 ml Pack523.002058(E)30.06.2017737Snake Venom Antiserum- Soluble/ Liquid PolyvalentInjectionEach Pack (10 ML)406.14884(E)28.02.2018738Sodium BicarbonateInjection 7.5%1 ml1.312058(E)30.06.2017739Sodium BicarbonateInjection 8.4%1 ml1.212058(E)30.06.2017740Sodium ChlorideInjection 0.9%1000ml Glass55.702058(E)30.06.2017741Sodium ChlorideInjection 0.9%1000ml Non-Glass43.942058(E)30.06.2017742Sodium ChlorideInjection 0.9%100ml Glass16.482058(E)30.06.2017743Sodium ChlorideInjection 0.9%100ml Non-Glass14.842058(E)30.06.2017744Sodium ChlorideInjection 0.9%250ml Glass22.212058(E)30.06.2017745Sodium ChlorideInjection 0.9%250ml Non-Glass19.952058(E)30.06.2017746Sodium ChlorideInjection 0.9%500ml Glass30.882058(E)30.06.2017747Sodium ChlorideInjection 0.9%500ml Non-Glass26.292058(E)30.06.2017748Sodium NitroprussideInjection 10 mg/ml1 ml24.232058(E)30.06.2017749Sodium ValproateInjection 100 mg/ml1 ml5.412058(E)30.06.2017750Sodium ValproateOral Liquid 2001 ml0.552058(E)30.06.2017

Pack)1 ml1.172058(E)30.06.2017802TramadolInjection 50mg/ml (upto 2 ml Pack)1 ml9.832058(E)30.06.2017803TramadolTablet 100 mg1 Tablet18.462058(E)30.06.2017804TramadolTablet 50 mg1 Tablet7.572058(E)30.06.2017805TramadolCapsule 100 mg1 Capsule9.012058(E)30.06.2017806Tranexamic acidInjection 100mg/ml1 ml14.022059(E)30.06.2017807Tranexamic acidTablet 500 mg1 Tablet16.302059(E)30.06.2017808TrastuzumabInjection 440 mg/50 mlEach Pack56,458.852058(E)30.06.2017809TrihexyphenidylTablet 2 mg1 Tablet1.142058(E)30.06.2017810TropicamideEye Drop 1%1 ml9.442058(E)30.06.2017811VancomycinPowder forInjection 1 gmEach Pack446.682059(E)30.06.2017812VancomycinPowder forInjection 250 mgEach Pack208.122059(E)30.06.2017813VancomycinPowder forInjection 500 mgEach Pack268.672059(E)30.06.2017814VecuroniumPowder forInjection 10 mgEach Pack177.462059(E)30.06.2017815VecuroniumPowder for Injection 4 mgEach Pack85.652059(E)30.06.2017816VerapamilInjection 2.5mg/ml1 ml1.092058(E)30.06.2017817VerapamilTablet 40 mg1 Tablet0.702058(E)30.06.2017818VerapamilTablet 80 mg1 Tablet1.302058(E)30.06.2017

Notes:-

• The ceiling prices are applicable with effect from 4.2018 (ceiling prices are inclusive of Wholesale Price Index (WPI) @3.43812% for the year 2017 over 2016).
• In respect of Gentamycin injection  40mg/ml,  Dexamethasone  injection  4mg/ml,  Paracetamol injection 150mg/ml, Glucose Injection 5%, Sodium  chloride Injection 9%, Glucose + Sodium chloride Injection 5%+0.9%, Water for Injection, Dicyclomine Injection 10mg/ml, Snake venom antiserum, Pheniramine Injection 22.75 mg/ml and Tetanus Toxoid injection, for any other pack size manufactured, the manufacturer shall approach NPPA for specific price approval for its formulations  along with the relevant market data   duly authenticated for fixation of the ceiling price. The formulation of Sodium Valproate includes combination of Sodium Valproate and Valproic Acid both together corresponding to Sodium Valproate of the stated strength.

• In respect of any other scheduled formulation, for which ceiling price is not mentioned above,  the manufacturer shall approach the NPPA for specific  price  approval  for  its  formulations along with the relevant market data duly authenticated for fixation of the ceiling
• All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus goods and services taxes as applicable) so fixed and notified by the Government,  shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in  the  above table plus goods and services taxes as applicable, if
• All the existing manufacturers of above mentioned scheduled formulations having MRP lower  than the ceiling price specified in column (5) in the above table (plus goods and services taxes  as applicable, if any), may  revise  the existing MRP  of their  formulations, on the basis  of WPI @ 43812% for year 2017 in accordance with paragraph  16(2)  of  DPCO, 2013,  read with para 13(2) of DPCO, 2013.
• The manufacturers may add goods and services taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of  the above  said
• The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
• As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the
• Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer  shall apply for prior  price approval of such new  drug to the NPPA  in Form I as specified under Schedule-II of the DPCO,
• The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form -III of Schedule-II of the DPCO, 2013 through Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA,  in respect of discontinuation of production and/or import of scheduled formulation in Form -IV of Schedule-II of the DPCO, 2013 at least six months prior  to the intended  date   of discontinuation.
• The manufacturers not complying with the ceiling price and notes specified hereinabove  shall be liable to deposit  the  overcharged  amount  along  with  interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,
• The notification under para 19 of DPCO 2013 vide SO 3090(E) dated  09.2017,  3091(E) dated 20.09.2017, SO 3723(E) dated 23.11.2017, SO 3724(E) dated 23.11.2017 and 3914(E) dated 08.12.2017 shall continue to be governed  under para 19 as stated in  the  said notifications except the ceiling prices stated above.

• Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s)